share

Dr. Derek Jones - Dermatology Research in Los Angeles

Due to his extensive experience researching in the field of cosmetic and general dermatology, Dermatologist Dr. Derek Jones is one of the most sought-after researchers to perform FDA trials on newer noninvasive cosmetic technologies. He was the lead investigator in the successful U.S. FDA trial for Kybella®. His research also led to the FDA approval of the leading wrinkle filler, Juvederm®, and to the eyelash growth product Latisse®. In addition, Dr. Jones has conducted investigations into the cosmetic effects of a number of botulinum toxins, including BOTOX® Cosmetic.

To learn more about Dr. Jones' work or to request an appointment with him, contact Skincare and Laser Physicians of Beverly Hills online or by phone at 310-246-0495.

He has a state-of-the-art facility dedicated to clinical trials and research. Dr. Jones has written more than 80 peer-reviewed articles and has presented more than 250 scholarly lectures on the research findings at professional meeting around the globe. He is currently testing the latest generation of muscle relaxant toxins, dermal fillers, and lasers with more than 100 patients enrolled in the studies. His team works diligently from Beverly Hills to remain at the forefront of research and technology.

Leading the Curve of Innovation:
Dr. Jones and his physician
associates have pioneered research
that lead directly to
U.S. market approval
of today's most popular injectables
including Botox®, Voluma®,
Juvederm®, Kybella®, Belotero®,
and many more.

Dr. Derek Jones is a Pioneer in His Field

If you are ready to schedule a consultation with Dr. Jones for the treatment of your choice, you can request a consultation with us online or call our office at 310-246-0495 for more information.

  1. Principle Investigator, Merz Pharmaceuticals. Phase 4 post approval study of Radiesse® for the Treatments of Hands with Moderate to Very Severe Dorsal Volume Loss. February 2016- Present.
  2. Principle Investigator, Galderma. Pivotal FDA trials on a new hyaluronic acid filler, Emervel®. 2010-present.
  3. Lead Investigator, Merz Pharmaceuticals. Pivotal FDA trials on MDF-100 alginate filler for nasolabial folds. 2009-present.
  4. Principle Investigator, Merz Pharmaceuticals. Investigator for FDA trials on botulinum toxin A (NT 201) for treatment of glabellar furrows. 2008-present.
  5. Lead Investigator, Allergan. Investigator for FDA trials on a new hyaluronic acid (Voluma®) for treatment of midface lipoatrophy. 2007-present.
  6. Principle Investigator, Evolus. Phase 3 study of efficacy of DWP-450 for treatment of moderate-to-severe glabellar lines. June 2014-September 2016.
  7. Principle Investigator, Evolus. Phase 2 study of DWP-450 for treatment of moderate-to-severe glabellar lines. June 2014-October 2016.
  8. Principle Investigator, Merz Pharmaceuticals. Phase 4 study to investigate the equivalence of incobotulinumtoxinA (Xeomin®) to onabotulinumtoxinA (BOTOX®) in the treatment of glabellar frown lines. 2013-2014.
  9. Principle Investigator, Lithera. Phase 2 study of LIPO-202 (salmeterol xinafoate (SX)) versus placebo for the reduction of localized subcutaneous fat in the abdomen area. 2013.
  10. Principle Investigator, Kythera. Phase 3B study of ATX-101 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental area in subjects with clinician reported submental fat rating scale grade 1 or grade 4. 2013.
  11. Principle Investigator, Allergan. Phase 3 study of Latisse® (topical bimatoprost solution) versus placebo for eyebrow growth. 2013.
  12. Principle Investigator, Kythera. Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area. 2012.
  13. Lead Investigator, Phase 4 Investigator Initiated Trial on Combination of BOTOX Cosmetic® and Juvederm® Ultra for Brow Enhancement. 2010-2011.
  14. Principle Investigator, Merz Pharmaceuticals. Investigator for FDA trials on a new hyaluronic acid filler (Belotero® Soft) for treatment of mild nasolabial folds. 2008.
  15. Principle Investigator, Allergan. FDA trials for hyaluronic acid fillers (Juvederm®) for perioral and lip rejuvenation. 2007-2008.
  16. Principle Investigator, Allergan. FDA trials on topical bimatoprost solution for eyelash growth. 2007-2008.
  17. Principle Investigator, Merz Pharmaceuticals. Investigator for FDA trials on a new hyaluronic acid filler (Belotero®). 2006-2008.
  18. Principle Investigator, Inamed/Allergan. Investigator for FDA trials on a new family of hyaluronic acid fillers (Juvederm®). 2004-2006.
  19. Principle Investigator, Abgenix and Quintiles: Protocol ABX-0204: Part II. A two part, multi-center, randomized, double-blind, placebo controlled, multiple dose clinical trial of ABX-IL8 (a monoclonal antibody IL-8 inhibitor) in patients with moderate to severe plaque psoriasis. 2001-2002.
  20. Principle Investigator, TEVA Pharmaceuticals. A Multi-Center, Double-Blind Placebo Controlled, Parallel Group Study Comparing Bioequivalence 2 Formulations of Metronidazole Gel 0.075% for Rosacea. 2001-2002.
  21. Investigator, RJ Development, Peabody, MA. FDA study investigator for SilSkin (highly purified 1000 cs silicone oil) in treating nasolabial folds, mid-malar depressions, oral commissures, and HIV associated facial lipoatrophy. 2001.
  22. Investigator, Rodenstock, Inc. Pre-market study of the clinical utility and applications of computerized, digital microscopy in the detection of malignant melanoma. 2000-2001.

If you are ready to schedule a consultation with Dr. Jones for the treatment of your choice, you can request a consultation with us online or call our office at 310-246-0495 for more information.

 

"WE ARE A PHYSICIAN ONLY PRACTICE OPERATING AT THE FOREFRONT OF AESTHETIC DERMATOLOGY"

  I accept the Terms of Use

 Send promotions

security code

Video Gallery

Get a quick look at why SCLS is so unique.

VIEW VIDEOS

Reduce Unwanted Fat